203 related articles for article (PubMed ID: 36842301)
21. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
22. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
23. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
24. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
25. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
26. [Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].
Deng L; Yang Y; Huang J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
[TBL] [Abstract][Full Text] [Related]
27. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
28. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
Awada G; Neyns B
Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
[TBL] [Abstract][Full Text] [Related]
29. MEK inhibitors for the treatment of non-small cell lung cancer.
Han J; Liu Y; Yang S; Wu X; Li H; Wang Q
J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199
[TBL] [Abstract][Full Text] [Related]
30. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
31. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
[TBL] [Abstract][Full Text] [Related]
32. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
33. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
34. [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].
Molnár E
Magy Onkol; 2020 Mar; 64(1):76-78. PubMed ID: 32181767
[TBL] [Abstract][Full Text] [Related]
35. Current Insights into the Role of BRAF Inhibitors in Treatment of Melanoma.
Singh AK; Kumar A; Thareja S; Kumar P
Anticancer Agents Med Chem; 2023; 23(3):278-297. PubMed ID: 35761499
[TBL] [Abstract][Full Text] [Related]
36. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
Dankner M; Wang Y; Fazelzad R; Johnson B; Nebhan CA; Dagogo-Jack I; Myall NJ; Richtig G; Bracht JWP; Gerlinger M; Shinozaki E; Yoshino T; Kotani D; Fangusaro JR; Gautschi O; Mazieres J; Sosman JA; Kopetz S; Subbiah V; Davies MA; Groover AL; Sullivan RJ; Flaherty KT; Johnson DB; Benedetti A; Cescon DW; Spreafico A; Zogopoulos G; Rose AAN
JCO Precis Oncol; 2022 Aug; 6():e2200107. PubMed ID: 35977349
[TBL] [Abstract][Full Text] [Related]
37. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
38. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
[TBL] [Abstract][Full Text] [Related]
40. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
Courand PY; Berger M; Bouali A; Harbaoui B; Lantelme P; Dalle S
Curr Oncol Rep; 2022 Mar; 24(3):265-271. PubMed ID: 35102484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]